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Abstract
Ubiquitin proteasome system (UPS) impairment, excessive cellular oxidative stress, and iron dyshomeostasis are key to 
substantia nigra dopaminergic neuronal degeneration in Parkinson’s disease (PD); however, a link between these features 
remains unconfirmed. Using the proteasome inhibitor lactacystin we confirm that nigral injury via UPS impairment disrupts 
iron homeostasis, in turn increasing oxidative stress and promoting protein aggregation. We demonstrate the neuroprotective 
potential of two novel 1-hydroxy-2(1H)-pyridinone (1,2-HOPO) iron chelators, compounds C6 and C9, against lactacystin-
induced cell death. We demonstrate that this cellular preservation relates to the compounds’ iron chelating capabilities and 
subsequent reduced capacity of iron to form reactive oxygen species (ROS), where we also show that the ligands act as anti-
oxidant agents. Our results also demonstrate the ability of C6 and C9 to reduce intracellular lactacystin-induced α-synuclein 
burden. Stability constant measurements confirmed a high affinity of C6 and C9 for  Fe3+ and display a 3:1 HOPO:Fe3+ 
complex formation at physiological pH. Reducing iron reactivity could prevent the demise of nigral dopaminergic neurons. 
We provide evidence that the lactacystin model presents with several neuropathological hallmarks of PD related to iron 
dyshomeostasis and that the novel chelating compounds C6 and C9 can protect against lactacystin-related neurotoxicity.
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Hepc  Hepatocyte-secreted hormone
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesul-
fonic acid
HOPO  Hydroxypyridinone
1,2-HOPO  1-Hydroxypyridin-2-one
HRP  Horseradish peroxidase
ICP-MS  Inductively-coupled-plasma mass 
spectroscopy
iROS  Intracellular ROS
IRP2  Iron regulatory protein 2
LBs  Lewy bodies
LMCT  Ligand to metal charge transfer band
MS  Mass spectrometry
MFI  Mean fluorescence intensity
MTS  (3-(4,5-Dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium
Mfrn2  Mitoferrin-2
NMR  Nuclear magnetic resonance
PD  Parkinson’s disease
ppm  Parts per million
PBS  Phosphate-buffered saline
PAGE  Polyacrylamide gel electrophoresis
PVDF  Polyvinylidene difluoride
RIPA  Radioimmunoprecipitation assay
ROS  Reactive oxygen species
RT  Room temperature
RPM  Rotations per minute
6-OHDA  6-Hydroxydopamine
SDS  Sodium dodecyl sulfate
SD  Standard deviation
SN  Substantia nigra
SNpc  Substantia nigra pars compacta
TBA  Thiobarbituric acid
UPS  Ubiquitin proteasome system
UV  Ultraviolet
Introduction
Parkinson’s disease (PD) associates with the progressive 
degeneration of nigro-striatal dopaminergic (DAergic) neu-
rons in the substantia nigra pars compacta (SNpc), result-
ing in the development of motor symptoms such as resting 
tremor, muscle rigidity, and bradykinesia (Poewe and Mahl-
knecht 2009). Although the exact cause of idiopathic PD 
remains unknown, excessively high levels of localized iron 
concentrations within the brain has been deemed contribu-
tory to progressive PD (Sian-Hülsmann et al. 2011). Iron 
cytotoxicity ensues when iron exists in a labile state and 
elicits a cascade of cellular deleterious events, driven by 
participation in redox reactions i.e., the Haber–Weiss cycle 
(Halliwell and Gutteridge 1984). The pathogenic mechanism 
underlying iron-mediated cellular damage and eventual neu-
ronal death seen in PD-affected brains likely involves exces-
sive generation of intracellular free radicals [e.g., reactive 
oxygen species (ROS)], which eventually overwhelms the 
cell’s antioxidant- or radical scavenging defense systems. 
This includes reducing levels of glutathione, a prominent 
brain anti-oxidant, resulting in oxidative damage to lipids, 
proteins, DNA, and mitochondria (Dixon and Stockwell 
2014). SNpc DAergic neurons are particularly vulnerable 
to oxidative stress. Mechanisms underlying such selective 
vulnerability include nigral DAergic neurons’ high iron 
levels and dopamine (DA) molecules’ high rate of oxygen 
utilization (Sayre et al. 2005). The extensive SNpc DAergic 
damage seen in PD-affected brains contrasts with normal 
ageing, during which iron is more likely to be deposited in 
a different portion of the SN, the pars reticulata part (Mas-
troberardino et al. 2009).
The ubiquitin proteasome system (UPS), a critical regu-
lator of protein homeostasis in eukaryotic cells is deemed 
essential for maintaining iron homeostasis (Thompson and 
Bruick 2012). Under non-pathological conditions, the UPS 
keeps the cellular environment free of misfolded and defec-
tive proteins; however, several neurodegenerative diseases, 
including PD, is characterised by proteasomal dysfunction, 
resulting in accumulation of aggregation-prone proteins and 
thus aberrant iron homeostasis. In particular, α-synuclein 
(α-SYN), an abundantly expressed 140-amino acid protein 
encoded by SNCA, involved in various cellular processes 
including DA release and -reuptake (Abeliovich et al. 2000; 
Braak et al. 2003), undergoes sequential aggregation during 
progressive PD, to form so-called intracellular Lewy bodies 
(LBs) and Lewy neurites, which underlies PD pathology. 
Experimental evidence supports the notion that abnormal 
α-SYN aggregates spread from brainstem to neocortex, 
propagating from cell-to-cell in a prion-like manner (Watts 
et al. 2013).
The realisation that protein fibrillisation comprises a fun-
damental pathological hallmark of PD-affected brains has 
resulted in increasing use of proteasome inhibitors for mod-
eling PD both in vitro and in vivo, thereby serving as a test 
bed for novel therapeutic strategies. The microbial metabolite 
lactacystin induces a PD-like motor phenotype in rodents, 
concomitant with loss of DAergic cell bodies in the SNpc 
and DAergic terminals in the striatum, striatal DA depletion, 
as well as α-SYN accumulation in remaining SN DAergic 
neurons (McNaught et al. 2002; Lorenc-Koci et al. 2011; 
Pienaar et al. 2015a, b; Savolainen et al. 2017). For instance, 
mice intracerebrally microinjected with lactacystin revealed 
increased iron deposition in the SN, accompanied by nigral 
DAergic neurodegeneration (Zhu et al. 2010). Although the 
exact mechanism by which iron deposition associates with lac-
tacystin neurotoxicity remains unknown, this study suggested 
that this may relate to abnormal regulation of iron-related 
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proteins, including iron regulatory protein 2 (IRP2) and diva-
lent metal transporter 1 (DMT1) (Zhu et al. 2010). Further 
evidence that iron plays an important role in PD neuropa-
thology induced by UPS impairment stems from reports that 
pharmacological iron chelators such as desferoxamine (DFO) 
and 5-(4-(2-hydroxyethyl) piperazin-1-yl (methyl)-8-hydrox-
yquinoline (VK-28) prevented iron deposition and DAergic 
neurodegeneration in lactacystin-injected mice (Zhang et al. 
2005; Zhu et al. 2007).
Hence, due to the putative interplay between lactacystin-
induced UPS impairment and iron misregulation, this toxin 
serves as a useful tool for exploring how an interplay between 
the iron-regulating and UPS pathways result in the DAergic 
neuronal degeneration and abnormal intracellular α-SYN-
containing intracellular aggregates seen in PD. In addition, it 
serves as a translational cell model for assessing the disease-
modifying potential of chelators of labile iron. The therapeutic 
use of iron chelators for removing excessive amounts of iron 
and/or redox-silencing in PD patients is receiving consider-
able research and clinical attention (Ward et al. 2015). Previ-
ous work performed on rats showed that brain-permeable iron 
chelators can alleviate lactacystin-induced DAergic neuronal 
degeneration, restore proteasome activity and reduce the pres-
ence of ubiquitin-positive intracellular inclusions in the SN 
(Zhang et al. 2005; Zhu et al. 2007).
Here we provide physicochemical information on two novel 
1,2-HOPO-based iron chelators, compounds C6 and C9 to 
quantify their chelating power towards  Fe3+, the protonated 
species distribution and their complex formation with  Fe3+ in 
relation to pH. We previously studied C6 and C9 in SH-SY5Y 
human neuroblastoma cells exposed to 6-hydroxydopamine 
(6-OHDA) neurotoxic insult (Workman et al. 2015), which 
reproduce some features of PD-related neuropathology. These 
include increased ROS production, mitochondria functional 
inhibition and iron liberation from storage proteins such as 
ferritin (FT), resulting in DAergic neuronal death thereby 
impairing DA homeostasis (Alberio et al. 2012). The current 
study provides further characterization of the antioxidant, neu-
roprotective and neurorescuing properties as well as the abil-
ity by the novel iron chelators to reduce α-SYN intracellular 
load in SH-SY5Y cells treated with lactacystin. We compared 
the compounds’ effects to the clinically approved 3-hydroxy-
4(1H)-pyridinone chelator, deferiprone (DFP), which was 
shown to improve PD patients’ motor and non-motor symp-
toms (Moreau et al. 2018).
Material and methods
Materials
Distilled water was purified by passaging through a mixed 
bed of ion-exchanger (R3 type; Thermo Fisher Scientific, 
Waltham, MA, USA) and activated carbon (the Oxygen 
Release Compound type; Thermo Fisher Scientific). Metal 
cation solutions were prepared from their perchlorate salts. 
Their concentrations were determined via colorimetric titra-
tions with ethylenediaminetetraacetic acid (EDTA) solution 
(Titriplex III, Merck Millipore, Watford, UK), in accordance 
with standard procedures (Fish 1988; Skoog et al. 2000). 
Sodium hydroxide and perchloric acid were used to adjust 
pH during titrations. The ionic strength of all solutions was 
fixed at 0.1 M using sodium perchlorate.
Potentiometry
The protonated forms of the ligands C6 and C9  (10–3 M) 
and the stability constants (log β) of their complexes with 
 Cu2+ ([L]/[Cu2+] ≈ 2.2, L = C6 or C9) were characterized by 
potentiometric titrations in water in accordance with a previ-
ously published procedure (Gillet et al. 2017) using an auto-
matic titrator system (904 DMS Titrino, Metrohm Limited, 
Switzerland) with a combined glass electrode (6.0234.100; 
Long Life, Metrohm Limited, Switzerland) filled with 0.1 M 
NaCl. The  Fe3+ complexes were already fully formed at pH 
2 and could therefore not be studied via this technique.
The potentiometric data were refined with the Hyperquad 
2008 program (Gans et al. 1996), which uses non-linear 
least-squares methods, considering the formation of metal 
hydroxide species. The titration of each system was repeated 
in triplicate. The distribution curves, as a function of the pH 
of the protonated forms of C6, C9 and their  Cu2+ complexes, 
were calculated using the Hyperquad Simulation and Specia-
tion (HySS 2009) software program (Alderighi et al. 1999).
Spectrophotometry
The protonation constant (log K) of a molecule is a key 
parameter that influences several of its drug-like properties, 
such as its lipophilicity, half-life, oral bioavailability, and 
the ability to cross cell membranes and also the blood–brain 
barrier. The log K values of the ligands C6 and C9 and their 
stability constants with  Cu2+ and  Fe3+ were determined by 
ultraviolet (UV)-visible spectrophotometric titrations versus 
pH, by simultaneously recording pH and UV–visible spec-
tra. Between p[H] = − 0.5 and p[H] = 2 (brackets indicate 
that the pH value was calculated) the batch technique was 
used, following a previously published procedure (Gillet 
et al. 2017).
Direct titrations were carried out between pH 2 and 
12.5. For the protonation studies, an aliquot of 30 ml 
of ligand C6 or C9 solution was introduced into a ther-
mostat-jacketed cell (25.0(2) °C). A known volume of 
perchloric acid solution was added to adjust the pH to 2 
and a dynamic titration was carried out by adding known 
volumes of NaOH solution using a Metrohm 904 Titrino 
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equipped with a Dosino 800 burette driven by the ver-
sion 2.5 TiAmo software. The titrator was interfaced with 
an Agilent Cary 60 UV–visible spectrophotometer which 
automatically recorded a spectrum after an equilibration 
time of 2 min, following each addition of base. The com-
plexation studies of C6 and C9 with  Fe3+ and  Cu2+ were 
carried out in the same way, on L:M stoichiometric ratios 
([L]/[Fe3+] = 3.2 and [L]/[Cu2+] = 2.2).
Competition experiments with EDTA in HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer 
(pH 7.4) were also carried out using the batch technique. 
Each batch sample contained an equivalent concentration of 
 FeL3 complex ([L]/[Fe3+] = 3.2, L = C6 or C9) and increas-
ing amounts of EDTA (0 < [EDTA]/[Fe3+] < 1). The sample 
was left to equilibrate overnight before a UV–visible spec-
trum and the same was recorded. All the spectrophotometric 
data were fitted with HypSpec software (https ://www.hyper 
quad.co.uk) (Gans et al. 1996), for calculating the protona-
tion constants of the ligands, the stability constants (log β) 
of the formed species and the coordination model of the 
studied systems.
Distribution coefficients
The lipophilicity of the ligands C6 and C9, along with their 
corresponding  Fe3+ complexes, were determined by calcu-
lating their respective distribution coefficient (log D7.4) val-
ues using the Shake Flask method, by referring to the pub-
lished method of Ma and colleagues (Ma et al. 2012). The 
method rests on the principle that the solute’s distribution is 
determined as a ratio of concentrations of the test compound 
in a solution mixture, consisting of two immiscible phases, 
namely n-octanol and aqueous HEPES buffer (pH 7.4).
2,2‑Diphenyl‑1‑picrylhydrazyl assay
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay was per-
formed with C6 and C9, in accordance with previously 
published methods (Blois 1958). For this, 50 µl of different 
concentrations of C6, C9 and DFP (0.01 to 0.1 mg/ml in 
methanol) was dissolved in 2 ml of DPPH methanolic solu-
tion (the concentration was adapted to achieve an absorb-
ance of ~ 1). The samples were shaken vigorously and were 
allowed to stand until the reaction reached steady-state. The 
absorbance of the samples was then measured at 515 nm 
using a UV–visible absorption spectrophotometer (UV-2401 
PC; Shimadzu Corporation, Kyoto, Japan). Scavenging of 
DPPH free radicals was calculated as: DPPH scavenging 
activity (%) = [(Ac − At)/Ac] × 100 where, Ac is the absorb-
ance of the control tube (containing all reagents except the 
test compound), while At is the absorbance of the test tube.
Deoxyribose degradation assay
To investigate the origin of the antioxidant properties of the 
ligands (direct  OH. scavenging activity or indirect inhibition 
of the Fenton reaction through Fe chelation), we applied 
the deoxyribose degradation assay (DDA) with  FeCl3 or 
FeEDTA as the  Fe3+ source, as previously described (Chaves 
et al. 2012). Briefly, a mixture of ascorbic acid,  H2O2 and 
FeEDTA (or  FeCl3) complex generated hydroxyl radicals 
via the Fenton reaction. These radicals subsequently react 
with deoxyribose to generate malondialdehyde, which in 
turn reacts with thiobarbituric acid (TBA) to form a pink 
chromogen. Each assay consisted of 20  mM  KH2PO4/
K2HPO4 buffer (pH 7.4), 2.8 mM deoxyribose, 0.1 mM 
 FeCl3, 0.1 mM EDTA, different concentrations of the ligand 
(0.6–3.0 mM), 0.2 mM  H2O2 and 0.1 mM ascorbic acid, in 
a final volume of 1.0 ml. Solutions of  FeCl3–EDTA,  H2O2 
and TBA, were made up immediately before use, with ascor-
bic acid that was added to initiate the reaction. In the pres-
ence of  OH., deoxyribose is degraded to a product which, 
when heated with TBA at acidic pH forms a pink chromo-
gen. After incubating the solutions for 1 h at 37 °C, the 
color reaction was developed by adding 1 ml of 2.8% (w/v) 
trichloroacetic acid and 1 ml of 1% (w/v) TBA to 0.05 M 
NaOH, followed by heating the reaction mixture for 30 min 
at 100 °C. The solutions were cooled, after which absorb-
ance was measured spectrophotometrically at a wavelength 
of 532 nm (λmax). Controls containing no deoxyribose in the 
reaction mixture were included for all ligand concentrations.
Cell culture, drug and neurotoxin treatment 
paradigm
Undifferentiated, adherent human neuroblastoma SH-
SY5Y cells (cat #: ECACC 94030304) were obtained 
from the European Collection of Authenticated Cell Cul-
tures (ECACC, Salisbury, UK). Cells were maintained in 
complete growth medium (Dulbecco’s Modified Eagle’s 
medium (DMEM) with Ham’s F12, 10% foetal bovine serum 
(FBS; Sigma-Aldrich, St. Louis, MO, USA), 10,000 units/
ml penicillin (Life Technologies, Carlsbad, CA, USA) and 
10,000 µg/ml streptomycin (Life Technologies) at 37 °C 
in 5%  CO2. Cells were plated in 96-well plates for 48 h at 
4000 cells/100 µl DMEM with 10% FBS for determining 
cell viability (determined by hemocytometer cell count) with 
a similar density used for Western immunoblotting, whilst 
20,000 cells/100 µl DMEM with 10% FBS was plated for 
measuring ROS levels. For assessing the ability of C6 and 
C9 to provide cytoprotection against proteasome inhibi-
tion via lactacystin, either C6, C9 or DFP, all at a dose of 
100 µM (dissolved in media), was added to the cell cultures 
for 24 h, followed by addition of the irreversible proteasome 
inhibitor, lactacystin (5 µM, Enzo Life Sciences, UK) for a 
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further 24 h. We also determined the cell death rescue effects 
of each of the compounds of interest compared to DFP, by 
treating the cell cultures for 24 h with lactacystin, followed 
by 100 µM of C6, C9 or DFP. Stock solutions of lactacystin 
were prepared in fresh medium containing 100% dimethyl 
sulfoxide (DMSO), which was diluted in fresh medium, to 
a final DMSO concentration of 0.05%. Control conditions 
were included for all biochemical assays, i.e., for the cyto-
protection assay, the control cells were incubated with the 
compound of interest for 24 h, followed by treatment with 
the toxin’s vehicle (0.05% DMSO, dissolved in media) for 
another 24 h, whilst for the rescue assay, the compound-
toxin vehicle treatment protocols were reversed.
Inductively‑coupled‑plasma mass spectroscopy
Iron, copper and zinc levels were measured via inductively-
coupled-plasma mass spectroscopy (ICP-MS), similar to a 
previously published protocol (Duce et al. 2010). In brief, 
150 µg of total protein was lyophilized before resuspension 
in 100 µl Aristar-grade nitric acid (69% v/v), overnight at 
RT. Samples were then heated at 90 °C for 1 h, before add-
ing an equivalent volume of 30% hydrogen peroxide  (H2O2; 
Merck Millipore). Samples were then incubated for 15 min 
at RT before heating for 30 min at 70 °C. To evaluate metal 
content against calibration standards (IMS-102; Ultra Sci-
entific, North Kingston, RI, USA) samples were diluted in 
double-distilled water until within quantifiable parameters 
using a NexION 350X ICP-MS (PerkinElmer, Waltham, 
MA, USA). Each sample was measured in triplicate and 
normalized to its total protein concentration.
Cell viability assay
Cell viability was assessed via a 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay, which utilizes the abil-
ity of mitochondria to reduce a substrate (MTS) into a 
soluble formazan product. For the assay, the CellTiter 96 
 AQueous One Solution cell proliferation colorimetric assay 
kit was used, in accordance with the manufacturer’s instruc-
tions (Promega, Madison, WI, USA). The MTS assay was 
performed using 96-well plates containing the treated cells. 
Following the treatment paradigms, 20 µl MTS reagent was 
added to each well, and the plates incubated at 37 °C for 3 h. 
The absorbance of the solution was read at 490 nm using a 
FLUOstar Omega spectrophotometer (BMG LabTech, Ger-
many). Experiments were performed in triplicate. Results 
were expressed as a percentage of control. The MTS assay-
derived data were validated by means of traditional trypan 
blue dye exclusion. For this, an aliquot of cell suspension in 
PBS was mixed with an equal volume of trypan blue solu-
tion (0.4% in PBS). In total, 10 µl of cells were added to a 
Neubauer haemocytometer chamber and the average number 
of cells was counted by an observer blind to treatment pro-
tocol. Cell death was expressed as percentage trypan blue 
positive cells per total population of stained and unstained 
cells.
Intracellular and extracellular ROS level 
measurements
Production of intracellular ROS (iROS) and also extra-
cellular ROS (eROS) was determined using the substrate 
dihydrorhodamine  (DHR)-123 (Sigma-Aldrich), a non-
fluorescent laser dye that becomes oxidized by ROS to the 
fluorescent Rhodamine 123 (Kirchner et al. 2012). For meas-
uring iROS levels using the DHR-123 assay, we followed 
published guidelines (Wang et al. 2016; Das et al. 2015), 
as well as the manufacturer’s guidelines, available online 
(https ://www.sigma aldri ch.com/catal og/produ ct/sial/d1054 ). 
Briefly, SH-SY5Y cells (20,000 cells/100 µl DMEM for each 
well) were plated and cultured in 96-well plates for 48 h. 
Lactacystin (5 µM, Enzo Life Sciences) was then applied 
for 24 h, followed by treatment with either C6, C9 or DFP 
(all at 100 µM, dissolved in medium) for a further 24 h, 
without removal of the lactacystin solution. After the 48 h 
period of incubating the cells with the toxin and drugs, using 
typical incubator conditions (5%  CO2, 95% air at 37 °C), 
the medium was discarded, and the cells were incubated 
in the dark with 100 µl of 10 µM DHR-123 solution and 
supplement-free growth medium, at typical incubator condi-
tions for 30 min, similar to the DHR-123 incubation period 
proposed in several published protocols (e.g., Das et al. 
2015; Meng et al. 2016; Wang et al. 2016). Subsequently, 
the medium was removed and the cells were washed with 
PBS (× 3) before immediate analysis of the fluorescence 
intensity of each well using a microplate reader (FLUOstar 
Omega), with an excitation filter of 485 nm and an emission 
filter of 520 nm.
For determining eROS levels, the procedure was repeated 
until after the cells had been incubated with DHR-123 solu-
tion, for the same period of time and dose as was used for 
determining iROS. The culture media was then transferred 
(without detaching the adherent cells) to a fresh 96-well 
microplate for measuring extracellular fluorescence inten-
sity, as described above.
Cell lysis, protein extraction and protein estimation
For preparing whole cell lysates, cells were washed with 
ice-cold phosphate-buffered saline (PBS), harvested and 
then lysed in radio-immunoprecipitation assay (RIPA) 
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% sodium 
deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sul-
fate; Sigma-Aldrich), also containing a protease inhibitor 
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cocktail consisting of 4-(2-aminoethyl) benzenesulfonyl 
fluoride (2 mM), aprotinin (0.3 μM), bestatin (116 μM), 
E-64 (14  μM), leupeptin (1  μM) and EDTA (1  mM). 
The suspension was homogenized in a fresh Eppendorf 
tube by shaking for 15 min on ice. Samples were clari-
fied to remove denatured nucleic acid by centrifugation at 
14,000×g for 15 min at 4 °C. The protein containing the 
supernatant was then transferred to new tubes before total 
protein concentration was determined in each sample via a 
Bradford assay (Bradford Reagent, Sigma-Aldrich).
Western blots
SH-SY5Y cells (4000 cells/100 µl DMEM with 10% FBS) 
were cultured in 96-well plates for 48 h before lactacystin 
(5 µM, Enzo Life Sciences) treatment for 24 h, followed 
by the specific compound treatment protocols for a further 
24 h (resulting in cells being exposed to lactacystin for 
48 h). To prepare whole cell lysates, the cells were washed 
in ice-cold PBS, harvested and then lysed with RIPA 
buffer containing 4-2-aminoethyl benzenesulfonyl fluo-
ride (2 mM), aprotinin (0.3 μM), bestatin (116 μM), E-64 
(14 μM), leupeptin (1 μM) and EDTA (1 mM). The lysates 
were centrifuged at 13,000 rotations per minute for 15 min 
at 4 °C, with the supernatant used for analysis. Protein 
concentrations were determined using the Bradford protein 
assay (Bio-Rad Laboratories). Prior to immunoblotting, 
protein extracts were separated on a 10% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and then transferred to Immobilon-P polyvinylidene dif-
luoride (PVDF) membranes (Bio-Rad Laboratories) using 
an electrophoretic transfer cell (Mini Trans-Blot®, Bio-
Rad Laboratories) and by applying constant current at 
200 mA for 1.5 h. The blots were blocked with 5% w/v 
dried milk in PBS for 90 min before incubating for 4 h in 
a solution containing rabbit anti-α-SYN primary antibody 
(1:1,000 dilution; Cell Signalling Technology, UK) on a 
shaker at 4 °C. After incubation with horseradish peroxi-
dase (HRP)-conjugated secondary antibody (polyclonal 
goat anti-rabbit, 1:3,000 dilution, Abcam, Cambridge, 
UK) for 2 h at room temperature (RT), immunoreactive 
proteins were visualized by enhanced chemiluminescence 
detection kit (Pierce™ ECL plus Western Blotting Sub-
strate, Thermo Fisher Scientific). The light-emitting bands 
were detected with X-ray film. An anti-GAPDH (glycer-
aldehyde-3-phosphate dehydrogenase) antibody (poly-
clonal rabbit; 1:1,000 dilution, Chemicon International, 
Inc., Billerica, MA, USA) was used as a control. The 
band intensities were quantified by densitometric analysis 
using ImageJ software (v1.45 software, Wayne Rasband, 
National Institute of Health, USA).
Nuclear magnetic resonance spectroscopy
The potential trapping of the reactive lactone formed by lac-
tacystin (clasto-lactacystin β-lactone) by C6 was studied via 
1H Nuclear Magnetic Resonance (NMR) spectroscopy and 
mass spectrometry (MS) in two deuterated solvent systems, 
namely DMSO-d6 and 10% DMSO-d6 in  D2O. Lactacystin 
(200 μg, 5.313 × 10−7 mol) was dissolved in 0.2 ml DMSO-
d6, with 0.1 ml of this solution that was removed and diluted 
to a total volume of 0.5 ml with DMSO-d6. This solution was 
placed in an NMR tube and the 1H NMR spectrum recorded 
on a JEOL ECS400FT Delta spectrometer (399.78 MHz 
for 1H) to obtain a reference (in DMSO-d6). The remain-
ing 0.1 ml of lactacystin solution was diluted to a volume 
of 1 ml with  D2O; the spectrum was recorded similarly (in 
10% DMSO-d6 in  D2O). Reference NMR spectra of C6 
(1.328 µM) in each of these solvent systems were obtained. 
For each solvent system, 0.2 ml (1 molar equivalent) of C6 
stock solution was added to the NMR tube containing lac-
tacystin. The NMR tube was then inverted to mix several 
times, before the 1H NMR spectrum was recorded. A total 
of three additions (3 molar equivalents) of C6 stock solution 
were added to each NMR tube and the NMR spectra were 
recorded each time. PBS (0.2 ml, pH = 7.4) was then added 
to each NMR tube to raise the pH from 7.0 to 7.4 and the 
NMR spectra were re-recorded. Aliquots from each NMR 
tube were then analysed by MS using electrospray ionization 
(ThermoFinnigan LCQ Advantage Max mass spectrometer, 
ThermoFinnigan Corporation, San Jose, CA, USA).
Statistical analyses
Statistical significance was calculated by means of a one-
way ANOVA followed by a Dunnett’s post-hoc test to 
assess for differences between the groups. Statistical tests 
were performed using GraphPad Prism version 7 (Graph-
Pad Software, Inc., CA, USA). A p value ≤ 0.05 was con-
sidered statistically significant. Values are expressed as the 
mean ± standard deviation (SD) of triplicate observations.
Results
Physicochemical characterization
A detailed physicochemical study was carried out in aqueous 
solution on ligands C6 and C9 to assess their coordination 
model, affinity for  Fe3+ and  Cu2+ and selectivity. The lipo-
philicity and antioxidant ability of the ligands and their  Fe3+ 
complexes were also evaluated via log  D7,4, as well as DPPH 
and DDA assay determination, respectively.
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Protonation properties versus pH
The protonation properties of ligands C6 and C9 were 
studied through both potentiometric titrations and UV–Vis 
absorption spectrophotometric titrations versus pH (Fig. 1a). 
The acido-basic properties of ligands C6 (Fig. 1b) and C9 
(Fig. 1c, d) as well as their metal complexes were also stud-
ied in strongly acidic conditions between p[H] − 0.5 and 2 by 
means of spectrophotometric titrations versus p[H] (brack-
ets indicate that the pH value was calculated). As such low 
p[H] cannot be measured with an electrode, the batch titra-
tion technique was used and the p[H] of the solutions was 
fixed by adding known volumes of standardized  HClO4 (see 
material and methods section for details). The ionic strength 
was not fixed below p[H] 1 in the batch titrations and no 
decomposition of the ligands was observed, even under 
Fig. 1  a Poten-
tiometric titrations of C6 
([C6] = 1.01 × 10−3 M) and C9 
([C9] = 9.96 × 10−4 M). b Spec-
trophotometric titrations versus 
pH of C6 ([C6] = 1.54 × 10−4 M, 
batch titration − 0.5 < pH < 2 and 
direct titration 2 < pH < 11.38). 
Spectrophotometric titration 
versus pH of C9 between 
c − 0.5 ≤ pH ≤ 2 (batch titra-
tion, [C9] = 3.0 × 10−4 M and 
d 2.02 ≤ pH ≤ 13.02 (direct 
titration, [C9] = 1.48 × 10−4 M). 
e Electronic spectra and 
f distribution curves 
([C6] = 1.54 × 10−4 M) of the 
protonated species of ligand 
C6. g Electronic spectra and 
h distribution curves of the 
protonated species of C9 
([C9] = 3.0 × 10−4 M). Solvent: 
 H2O, I = 0.1 M  (NaClO4), 
T = 25.0 °C for all measure-
ments
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highly acidic conditions. For C6, a log K2H was determined 
from the spectral variations in the batch titration between 
p[H] − 0.5 and 2 (Fig. 1b) and may be attributed to the pro-
tonation of the 2-oxo group, similarly to 1,2-HOPO (Gardner 
and Katritzky 1957). Similar titration of C9 showed no evi-
dence of protonation in this p[H] range (Fig. 1c), suggesting 
that the additional intra-molecular hydrogen bond between 
the carboxylic acid and the 2-oxo group precludes protona-
tion of this group.
The average protonation constant (log K) values (± SD) 
are shown in Table 1; those of DFP and 1,2-HOPO are given 
for comparison. Log K1H was attributed to the N–OH pro-
ton for both ligands and log K2H corresponds to the carbox-
ylic acid proton in the case of C9. Measurement of proto-
nation constants of C6 and C9 allowed us to calculate the 
electronic spectra of their protonated species (C6, Fig. 1e; 
C9, Fig. 1g), as well as their distribution diagrams (C6, 
Fig. 1f; C9, Fig. 1h). These showed that under physiologi-
cal pH conditions (pH 7.4), C6 exists primarily (96%) in 
its totally deprotonated form  (C6−), in accordance with a 
 logD7.4 value of − 1.71(7), while under similar conditions, 
DFP is primarily in its neutral form and has a log D7,4 value 
of − 0.77(2) (Table 1). At this pH, C9 existed as a mix of its 
totally deprotonated form  (C92−, 80%) and monoprotonated 
form  (C9H−, 20%) with the hydroxamic acid group being 
protonated. These low protonation constants suggest that C6 
and C9 would have a poor ability to cross cell membranes 
via passive diffusion.
However, despite their relatively low protonation con-
stants, both C6 and C9 clearly reduced intracellular  Fe3+ in 
the SH-SY5Y cells, as was revealed by our results that labile 
iron was reduced which resulted in downstream beneficial 
effects, as discussed later.
Complex formation with  Fe3+ and  Cu2+ versus pH
Similar to the protonation study, spectrophotometric batch 
(− 0.5 < p[H] < 2) and direct (2 < pH < 12) titrations were 
then carried out on the  Fe3+ complexes of ligands C6 
(Fig. 2a, b) and C9 (Fig. 2c, d). The titrations showed the 
appearance of a ligand to metal charge transfer band (LMCT) 
centered around 480 nm for both ligands, characteristic of 
the complexation of  Fe3+. This band undergoes a hyper- and 
hypsochromic shift to 410 nm as pH increases, sign of the 
successive coordination of one, two, and three bidentate 
ligands to the  Fe3+ cation to achieve a hexacoordinate com-
plex. When the pH continues to increase, a decrease of the 
charge transfer band was observed suggesting the substitu-
tion of ligands in the  Fe3+ coordination sphere by hydroxide 
anions until the total release of  Fe3+ and its precipitation as 
Fe(OH)3, as suggested by the total loss of the LMCT band 
and a general increase in noise and baseline in the titration 
of the complexes above pH 9.8 (Fig. 2b, d).
For both ligands, the presence of a hydroxylated complex, 
 FeL2(OH)2 (L = C6, C9), was observed before precipitation 
occurred. For ligand C9, that exhibited a non-coordinating 
carboxylic acid function, the additional formation of the 
protonated Fe(C9)H species at a very acidic pH was also 
observed. The overall stability constants (log β) of the 
observed species are shown in Table 2, which also shows 
that the pFe values of both C6 and C9 are very similar, and 
around one order of magnitude lower than that of DFP.
To chelate labile  Fe3+ and prevent oxidative damage, a 
therapeutic iron chelator must be able to form a reasonably 
stable  FeL3 complex (L = chelator) in which the inner coor-
dination sphere of  Fe3+ is fully saturated. However, the sta-
bility of the complex need not be so high as to result in total 
removal of  Fe3+ from either the cell or from  Fe3+-saturated 
transferrin. Determination of the stability constants of the 
C6 (Fig. 2e) and C9 (Fig. 2g)  Fe3+ complexes allowed us 
to calculate the electronic spectra of their protonated spe-
cies and compile their respective distribution diagrams (C6, 
Fig. 2f; C9, Fig. 2h), to show the major complex species 
present at physiological pH.
Competition experiments were carried out with EDTA in 
HEPES buffer at pH 7.4 to verify our complexation model 
and confirm the  FeL3 stability constants of C6 (Fig. 3a) and 
C9 (Fig. 3b), where  FeL3 should be the only species present 
(L = C6 or C9). The fitting of the data confirmed the pres-
ence of a single  FeL3 species for both ligands. The condi-
tional stability constants of the  FeL3 complexes were deter-
mined and converted to overall stability constants (Ringbom 
1963) which were found to be in good agreement with those 
obtained from the spectrophotometric titrations versus pH 
(Table 2).
Since  Cu2+ is also redox-active and implicated in PD 
pathogenesis, we also studied the  Cu2+ binding affinity 
of C6 and C9. In the case of  Cu2+ complexation, spectro-
photometric titrations versus pH showed the successive 
formation of CuL and  CuL2 complexes for both C6 and 
C9 ligands (Fig. 4a–d), followed by decomplexation and 
precipitation of Cu(OH)2 above pH 9 (Fig. 4e, f). Similar 
to  Fe3+ complexation, ligand C9 showed the additional 
formation of the protonated Cu(C9)H species. The affin-
ity of C6 and C9 (Table 2) for  Cu2+ was ca. 7 orders of 
Table 1  Successive protonation constants (log K) and partition coef-
ficients (log  D7.4) of C6, C9, DFP and 1,2-HOPO
Solvent:  H2O, I = 0.1  M  (NaClO4), T = 25.0  °C. The numbers given 
in parentheses correspond to the SD expressed to the last significant 
figure
C6 C9 DFP [56] 1,2-HOPO [57]
log K1H 6.02(5) 6.9(1) 9.77 5.81(2)
log K2H − 0.53(6) 3.70(6) 3.68 − 0.9(3)
log D7,4 − 1.71(7) / − 0.77(2) /
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magnitude lower than their affinity for  Fe3+, suggesting 
that both compounds have excellent selectivity for  Fe3+ 
over  Cu2+ (Table 2). This may be due to  Cu2+ being a 
softer Lewis acid than  Fe3+ and therefore having a lower 
affinity for hydroxypyridinones (HOPOs), which are hard 
Lewis bases, according to Pearson’s hard-soft acid base 
theory (Pearson 1963).
Distribution coefficients
The distribution coefficients (log D7,4) between an n-octanol 
phase and a HEPES-buffered aqueous phase at pH 7.4 were 
determined for ligand C6 (log D7,4 = − 1.71(7)) and its 
 Fe3+ complex (log D7,4 = − 0.18(2)) (Table 2). In the case 
of C9 and its  Fe3+ complex, no significant decrease in the 
Fig. 2  Spectrophotometric 
titration versus pH of  Fe3+ 
complexes of C6 between 
a − 0.75 ≤ pH ≤ 2 (batch titra-
tion, [C6] = 3.0 × 10−4 M) and 
b 2.02 ≤ pH ≤ 11.59 (direct 
titration, [C6] = 3.0 × 10−4 M) 
[C6]/[Fe3+] = 3.2. Spectropho-
tometric titration versus pH 
of  Fe3+ complexes of ligand 
C9 between c − 0.25 < pH < 2 
(batch titration) and d 
1.99 < pH < 12.02 (direct 
titration) [C9] = 3.0 × 10−4 M, 
[C9]/[Fe3+] = 3.2. e Electronic 
spectra and f distribution curves 
([C6] = 3.0 × 10−4 M) of the 
 Fe3+ complexes of C6. g Elec-
tronic spectra and h distribution 
curves ([C9] = 3.0 × 10−4 M, 
[C9]/[Fe(III)] = 3.2) of the  Fe3+ 
complexes of C9. Solvent:  H2O, 
I = 0.1 M  (NaClO4), T = 25.0 °C 
for all measurements
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absorbance values of the aqueous phase were observed in 
our experimental conditions, suggesting that this ligand and 
its complex are too hydrophilic to provoke substantial migra-
tion to the n-octanol phase at this pH. As with the protona-
tion constants, the low distribution coefficients of C6 and 
C9 suggest these compounds have a relatively low ability 
to cross cell membranes by passive diffusion. However, the 
possibility that the compounds could cross cell membranes 
by means of an active transport mechanism cannot be ruled 
out completely.
DPPH radical scavenging assay
To evaluate the antioxidant ability of C6 and C9, a  DPPH. 
free radical scavenging assay was carried out at pH 7.4. The 
kinetics of reaction suggested that these ligands can be clas-
sified as being slow (Mishra 2012). C6 showed a slower 
reaction rate than DFP, but reached a percentage of inhibi-
tion of DPPH of 84 ± 1%, similar to that of DFP, while C9 
reached a maximum of only 32 ± 5% (Fig. 5).
Mechanistic evaluation of the compounds’ 
antioxidant properties
To gain further insight into the inherent antioxidant proper-
ties of ligands C6 and C9 (at various concentrations), DDAs 
were performed. The results obtained for C6 (Fig. 6a) and 
C9 (Fig. 6b) were superimposed with the distribution curves 
of  FeL3, which was obtained from the complexation titra-
tion experiment previously described. In the presence of 
 FeCl3, the strong inhibition of deoxyribose degradation 
observed for both C6 and C9 was primarily due to their 
ability to strongly bind  Fe3+ at physiological pH (log β 
(Fe(C6)3) = 19,5 and log β (Fe(C9)3) = 18.9 at pH 7.4), thus 
preventing the formation of  OH. through the Fenton reac-
tion. These results suggest that the tris-bidentate complexes 
formed at this pH do not participate in the generation of  OH..
In the presence of Fe-EDTA, the level of inhibition 
tended to follow the formation of the  FeL3 complex (L = C6, 
C9), in accordance with the high stability of the  Fe3+ com-
plexes at this particular pH. This suggests that, under these 
experimental conditions, the antioxidant effect of the ligands 
Table 2  Overall stability 
constants (log β), metal 
affinities at physiological 
pH (pM) and distribution 
coefficients (log D7.4) for M-C6, 
M-C9, M-DFP and M-1,2-
HOPO complexes (M = Fe3+, 
 Cu2+)
Solvent:  H2O; I = 0.1 M  (NaClO4); T = 25.0 °C, βMLxHy = [MLxHy]/([M][L]x[H]y); charges were omitted for 
the sake of clarity. The numbers given in parentheses correspond to the SD, expressed to the last significant 
figure
a Values obtained from the competition experiments
b pM = − log[Mfree]total, [pH] = 7.4, [L] = 10−5 M, [M] = 10−6 M
log β C6 C9 DFP [58] 1,2-HOPO [59]
Fe3+ Cu2+ Fe3+ Cu2+ Fe3+ Cu2+ Fe3+ Cu2+
ML 10.43(1) 9.4(2) 12.2(3) 9.6(1) 15.01(1) 10.42(1) 10.6(1)3 7.29(2)
MLH / / 13.66(2) 12.6(2) / / / /
ML2 20.11(2) 15.8(2) 21.2(2) 15.4(2) 27.3(1) 19.09(1) 20.1(2) 13.06(4)
ML2H / / / / / 21.98(8) / /
ML2(OH)2 5.67(1) / 5.62(1) / / 8.49(3) / /
ML3 28.05(2)
28.6a
/ 28.2(1)
28.1a
/ 37.43(1) / 27.2(2) /
pMb 18.5 11.6 18.4 11.1 19.3 10.5 16.1 6.9
log D7,4 − 0.18(2) / − 1.8(6) / − 2.60(5) / /
Fig. 3  Spectrophotometric batch 
competition titration between a 
Fe(C6)3 ([C6] = 3.65 × 10−4 M, 
[C6]/[Fe3+] = 3.2) and 
EDTA (0 ≤ [EDTA]/
[Fe(C6)3] ≤ 1.2), and b Fe(C9)3 
([C9] = 3.54 × 10−4 M, [C9]/
[Fe3+] = 3.2) and EDTA 
(0 ≤ [EDTA]/[Fe(C6)3] ≤ 1.2). 
Solvent: Hepes buffer pH 7.4, 
I = 0.1 M  (NaClO4), T = 25.0 °C
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would be mainly due to the strong  Fe3+ chelation ability of 
ligands C6 and C9 that inhibits the Fenton reaction, rather 
than from direct scavenging of  OH• radicals. Furthermore, 
calculation of the  IC50 values suggested strongly that the 
1,2-HOPO based ligands C6  (IC50 = 0.74(1) mM) and C9 
 (IC50 = 0.61(1) mM) function at least as efficiently as anti-
oxidants such as DFP  (IC50 = 0.63(9) mM).
C6 and C9 treatment induces changes in neuronal 
labile metal content in lactacystin‑treated SH‑SY5Y 
cells
The post-test analysis of total intracellular iron levels meas-
ured by ICP-MS revealed that the application of lactacystin 
to the cells produced a significant increase of 27.6 ± 0.05% 
(p = 0.047) compared to untreated cells (Fig. 7a). However, 
lactacystin-treated cells, co-incubated with compound, 
restored iron levels to control levels. This was the case for 
Fig. 4  Spectrophotometric 
titration versus pH of a C6 with 
 Cu2+ ([C6] = 1.63 × 10−4 M, 
[C6]/[Cu2+] = 2) and b C9 with 
 Cu2+ ([C9] = 1.48 × 10−4 M, 
[C9]/[Cu2+] = 2). Electronic 
spectra of the  Cu2+ complexes 
of c C6 and d C9. Distribution 
curves of the  Cu2+ complexes 
of e C6 ([C6] = 1.63 × 10−4 M) 
and f C9 ([C9] = 1.48 × 10−4 M). 
Solvent:  H2O, I = 0.1 M 
 (NaClO4), T = 25 °C for all 
measurements
Fig. 5  Percentage inhibition of the DPPH radical by the iron chelators 
C6, C9 and DFP, at the steady state
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Fig. 6  Percentage inhibition 
of deoxyribose degradation 
by the ligands a C6 and b C9 
in the presence of  FeCl3 ( ×) 
or FeEDTA (filled triangle) 
and distribution curves of 
 FeL3 complexes versus ligand 
concentrations. Solvent: 
20 mM phosphate buffer pH 
7.4, [Fe] = [EDTA] = 0.1 mM, 
0 < [C6], [C9] < 3 mM
Fig. 7  a Iron levels, as measured by ICP-MS, following treatment of 
SH-SY5Y cells with lactacystin, were greatly increased; in contrast, 
all tested compounds reduced such levels to a range comparable to 
the non-toxin treated control cells. b Such iron chelation associ-
ated with neuroprotective activity shown by C6 and C9 against lac-
tacystin-induced degeneration of SHSY-5Y cells. In the absence of 
any of the compounds, incubation with lactacystin (5  μM) for 24  h 
decreased cell viability by > 75% (a, b). The compounds (100  µM) 
protected against neurotoxin-mediated cell death (cell viability was 
increased by C6: 54.3%, C9: 38.9% and DFP: 32.8%, relative to the 
toxin-only condition), where treatment with C6 provided most protec-
tion to the cells (***p = 0.0002). c Addition of C6 and C9, as well 
as DFP, also significantly rescued against such toxin-associated cell 
death. Cellular incubation with the two novel 1,2-HOPO derivatives 
or DFP (100  µM per compound) also rescued against lactacystin-
induced cell death (% cell viability increases compared to toxin-
only treatment were: C6: 37.2%, C9: 24% and DFP: 28%). The 
level of viable cells was measured at OD 490 nm using the CellTi-
ter  96® AQueous One Solution Cell Proliferation Assay (MTS, Pro-
mega). Experiments were carried out × 3 with each experiment done 
in triplicate. Data represent the mean ± SD
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both C6 (40.9 ± 0.04%, p = 0.003) and C9 (61.1 ± 0.03%, 
p = 0.0001), when compared to cells treated with lactacys-
tin only. At the compounds’ concentration used in this study 
(100 µM), only C9 (and not C6) showed a greater capability 
than DFP for reducing accumulated iron in the toxin-treated 
cells, where C9 reduced the lactacystin-induced high iron 
levels by a further 26.5 ± 0.03% (p = 0.0028) compared to 
DFP treatment.
To eliminate the possibility that lactacystin indirectly 
altered iron through modulation of total metal homeostasis 
and to assess whether these compounds had a general chelat-
ing effect on other divalent metals, levels of copper and zinc 
were also measured in the same conditions (data not shown). 
Exposure to lactacystin decreased the cellular stores of cop-
per (46.5 ± 0.004%) and zinc (28.3 ± 0.05%), but this change 
did not reach statistical significance. No statistical signifi-
cance was observed upon treatment with either C6 (copper 
decreased by 1.3 ± 0.003%; zinc increased by 29 ± 0.07%) or 
C9 (copper decreased by 26.8 ± 0.003%; zinc 3.7 ± 0.05%) 
of the lactacystin-treated cells. This was comparable to data 
obtained for DFP (copper increased by 3.9 ± 0.004%; zinc 
30 ± 0.03%).
Compound rescue and protection 
against lactacystin toxicity
The potential of C6 and C9 to rescue and protect against 
lactacystin-induced neurotoxicity was compared to DFP in 
SH-SY5Y cell cultures. Rescue was evaluated by the addi-
tion of the compound (for 24 h) after lactacystin exposure 
for 24 h, whereas protection was tested by the applica-
tion of compound (for 24 h) prior to lactacystin (also for 
24 h). In each condition the negative control comprised of 
compound-vehicle (dissolved in media) only. Lactacystin (in 
the absence of compound) reduced cell numbers compared 
to the untreated control cells, as seen in both the ‘protec-
tion’—(by 75.8 ± 6%, p < 0.0001) (Fig. 7b) and the ‘rescue’ 
assay (by 77.9 ± 12%, p < 0.0001) (Fig. 7c). In lactacystin 
exposed cells, treatment with C6 significantly increased cell 
survival when administered either prior (by 54.3 ± 20.3%, 
p = 0.0002) (Fig.  7b) or following (by 37.2 ± 12.8%, 
p < 0.0001) (Fig. 7c) neurotoxin exposure. C9 also revealed 
significant protective (by 38.9 ± 19.1%, p = 0.0206) (Fig. 7b) 
and rescue effects (by 24 ± 9.3%, p = 0.001) (Fig. 7c) against 
lactacystin-induced cell death. A similar neuroprotection (by 
32.8 ± 22%, p = 0.004) (Fig. 7b) and neurorescue profile 
(28 ± 9.1%, p = 0.0002) (Fig. 7c) as the two test compounds 
was observed with assessment of the known clinical chelat-
ing compound, DFP.
C6 and C9 reduce lactacystin‑induced production 
of intracellular and extracellular ROS
Levels of ROS produced intracellularly (iROS) or extracel-
lularly (eROS) were measured upon lactacystin treatment, 
followed by treatment with a compound of interest. Without 
addition of the compound, lactacystin-treated cells had a sig-
nificant increase in levels of iROS (139 ± 20.5%, p < 0.0001) 
(Fig. 8a) and eROS (106 ± 27.3%, p < 0.0001) (Fig. 8b), 
compared to untreated control cells. The addition of C6 to 
the toxin model produced a significant reduction in iROS 
(121.2 ± 43.5%, p = 0.0002) (Fig. 8a) and eROS (97.9 ± 34%, 
p = 0.0102) (Fig. 8b). This rescue effect was less so with 
addition of C9 [iROS: 74 ± 19%, p = 0.0002 (Fig.  8a); 
eROS: 78 ± 60.6%, p = 0.0102) (Fig. 8b)]. Intriguingly, the 
clinically available compound DFP was unable to exert 
Fig. 8  Fluorescence intensity values of a iROS levels and b eROS 
levels revealed that treatment with C6 and C9 reduced iROS by 
50.7% (****p = 0.0001) and 30.8%, (***p = 0.0003), respectively. 
Addition of DFP did not produce a notable effect on lactacystin-
induced increased iROS levels. A similar pattern was detected for the 
eROS levels, detected in the cell culture medium. Here, the addition 
of C6 (47.5%, ***p = 0.0005) and C9 (37.8%, **p = 0.0066) resulted 
in a significant reduction in the lactacystin-induced elevated eROS 
levels
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a significant reducing effect on either iROS (19 ± 16.7%, 
p = 0.2894) (Fig. 8a) or eROS levels (8 ± 34.5%, p = 0.7637) 
(Fig. 8b) that were increased by treatment with lactacystin.
C6 and C9 reduce lactacystin‑induced α‑SYN 
overexpression levels
Endogenously expressed α-SYN in SH-SY5Y cells 
was upregulated by incubation with lactacystin for 24 h 
(17.8 ± 0.18%, p < 0.0001) (Fig.  9). This response was 
negated by post-treatment with the compounds of inter-
est, producing a significant response with C6 (13.5 ± 0.3%, 
p = 0.0163) and DFP (25.8 ± 0.03%, p < 0.0001), while C9 
produced the most striking reduction in lactacystin-induced 
α-SYN protein levels (43.5 ± 0.08%, p < 0.0001) (Fig. 9).
NMR spectroscopy
The interaction of lactacystin with C6 was studied in both 
DMSO-d6 and 10% DMSO-d6 in  D2O in the absence and 
presence of PBS (with osmolarity, ion concentration and 
a pH of 7.4). This buffer was added to replicate the more 
physiologically relevant environment of the SH-SY5Y cells. 
Reference spectra of both C6 and lactacystin were first 
obtained in each of these solvent systems. Resonances due 
to lactacystin were assigned by comparing values to previ-
ously published 1H NMR data (Hayes et al. 2008).
Upon addition of 1 equivalent of C6 to a solution of lacta-
cystin in DMSO-d6, no spectral changes were observed, sug-
gesting there was no formation of the lactacystin-C6 adduct. 
Further additions of C6 (up to a total of 3 equivalents) again 
did not lead to the appearance of any new resonances for 
the lactacystin-C6 adduct, with only the resonances for lac-
tacystin and C6 being observed. When the NMR experi-
ments were conducted in 10% DMSO-d6 in  D2O, no spectral 
changes were observed. Similarly, addition of PBS to raise 
the pH also did not lead to any spectral changes and there 
was no evidence for formation of either the clasto-lactacys-
tin β-lactone or the lactacystin-C6 adduct. Finally, no new 
resonances were observed upon addition of three equiva-
lents of C6 to lactacystin, and this was also the case in the 
presence of phosphate buffer. MS analysis of the solutions 
from both solvent systems (data not shown) did not show 
the expected mass peaks due to the lactacystin-C6 adduct, 
confirming that there was no interaction between lactacystin 
and C6 under these conditions.
Should the lactacystin-C6 adduct have been formed 
(assuming that the hydroxymethyl group is the most nucle-
ophilic group in C6, see the discussion section), a new set 
of resonances for the three aromatic protons, and a new 
set of doublets for the methyl groups would be expected. 
In addition, the diastereotopic methylene protons would 
be expected to appear as a pair of doublets centered at ca. 
4.5 ppm (parts per million).
Discussion
The aim of the present study was to combine physicochemi-
cal characterization and cellular investigation of the treat-
ment effects of two novel 1,2-HOPOs, C6 and C9, that were 
produced in our lab, in a lactacystin cellular model of PD, 
with this model replicating key changes seen in both neu-
rotoxin animal models of the disease and also post-mor-
tem PD brains. As a first-in class inhibitor of the UPS, the 
mechanism that controls cell turnover and regulates protein 
catabolism in the mammalian cytosol and nucleus, lactacys-
tin exposure has been demonstrated as an experimentally 
useful tool for mimicking aspects of neurodegenerative dis-
eases that display deficits in clearing misfolded proteins, to 
lead to intracellular protein aggregation, cytotoxicity, and 
Fig. 9  Relative density of the 
western blots showing α-SYN 
expression in SH-SY5Y cells 
treated with lactacystin (5 µM), 
followed by 100 µM treat-
ment with either C6 (n = 3), 
C9 (n = 3) or DFP (n = 3). The 
insert shows a representative 
blot. α-SYN band intensities are 
reported as relative expression 
levels of α-SYN compared to 
GAPDH. C9 treatment induced 
the most significant α-SYN 
downregulation in lactacystin-
treated SH-SY5Y cells
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eventual cell death (Konieczny et al. 2014; Harrison et al. 
2015; Fenteany et al. 1995).
We compared the results obtained from testing C6 
and C9 to the clinically available oral iron chelator, DFP. 
This clinically licensed bidentate ferric chelator has been 
successfully used for over 2 decades against iron storage 
pathologies, including recent promising results achieved in 
a clinical phase-I trial conducted on a small cohort of PD 
patients, to reveal beneficial effect on patients’ motor symp-
toms (Moreau et al. 2018). Our results reveal that C6 and C9 
are capable of protecting and rescuing against lactacystin-
induced neuronal death, with our results implying strongly 
that the mechanism relates to the compounds’ ability to 
reduce levels of labile iron, which leads to reduced levels of 
ROS, as well as the ability to reduce abnormally high levels 
of α-SYN that the compounds mediated in the SH-SY5Y 
lactacystin cell model of PD.
Here we provide several lines of evidence for the abil-
ity by lactacysin to reduce the intracellular labile iron pool, 
and also demonstrate the ability of the novel compounds 
C6 and C9 to interact with  Fe3+ and thereby restore iron 
levels. This includes measuring intracellular levels of Fe-56 
(the most common isotope of iron) via ICP-MS, which 
revealed that application of lactacystin to the cells signifi-
cantly increased iron content compared to untreated cells. 
In contrast, the same measures showed that all the tested 
compounds reduced the toxin-induced iron accumulation in 
cells. Moreover, general agreement exists that a build-up 
of intracellular iron stimulates oxidative stress, and hence 
that iron accumulation, followed by oxidative stress typically 
precedes all other cellular changes, including changes in iron 
storage proteins (Devos et al. 2014). In this regard our results 
also show elevated levels of both iROS and eROS upon lac-
tacystin treatment compared to toxin untreated control cells, 
while administration of both novel compounds, but particu-
larly C6, exerted a significant iROS and eROS reducing 
effect. The association between lactacystin and the molec-
ular mechanisms responsible for absorption of iron and 
maintenance of iron homeostasis, as well as how our novel 
compounds might interact with these factors to restore iron 
homeostasis in this toxin model of PD, will require further 
investigation. Several iron response proteins have been iden-
tified, including ferritin (FT), a protein for binding and car-
rying iron mainly in the blood serum; mitoferrin-2 (Mfrn2), 
for importing iron into mitochondria, the iron exporter ferro-
portin (FPN) and also hepatocyte-secreted hormone (Hepc), 
an iron absorption inhibitor mainly produced by the liver 
(Finberg 2013; Wallace 2016). Previously published work 
provided insight into the interactions between lactacystin 
and some of these molecular iron regulators. In differenti-
ated SH-SY5Y cells exposed to lactacystin, Carroll and oth-
ers (2011) reported no change in protein expression levels of 
either TfR or FT, but saw upregulation for FPN and Mfrn2 
protein, but without concomitant changes in associated 
mRNA levels. This result, showing largely a lack of change 
in several known iron regulatory proteins, and inconsistency 
between changes at the transcription versus translation level 
for regulators that were altered, suggests that other factors 
such as increased labile iron and accumulation of oxidatively 
damaged proteins may rather account for lactacysin-induced 
cell death. Greater insight to better understand the nature of 
the molecular interactions between this UPS toxin and the 
elaborate mechanisms that have evolved to sense iron levels 
and adjust iron absorption and recycling to maintain iron 
homeostasis could deliver new diagnostic and therapeutic 
possibilities for iron-related disorders. However, such further 
studies may be best placed by utilizing an in vivo system, 
since the balance of iron homeostasis is maintained through 
a dynamic equilibrium between systemic tissues, and hence 
an animal system will allow for a comparison between vari-
ous body compartments, while molecular iron regulators 
identified so far have been shown to operate in man as well 
as rodents (Wallace 2016). In this regard, our previous work 
showed that rats that had received a unilateral nigral stere-
otaxic injection of lactacystin accurately mirror the behav-
ioural and neuropathological deficits shown by PD patients 
(Pienaar et al. 2015a, b; Sharma et al. 2020).
Also, in a previous study (Workman et  al. 2015) we 
showed that in SH-SY5Y cells pre-incubated with 50 μM 
of iron, subsequent exposure to either C6 or DFP changed 
protein expression levels of FT and TfR to levels seen in 
cells not treated with iron, while a non-iron binding con-
trol compound left the FT and TfR levels unaltered. Future 
experiments are warranted to identify all genes/protein 
products involved in the complex pathway devoted to iron 
regulation that C6, C9 (and clinically available DFP) can 
alter downstream of their capacity to bind iron and restore 
toxin-induced ROS, with most insight that may come from 
screens conducted in animals with targeted mutations in iron 
regulatory genes.
Although it remains unclear whether changes in iron reg-
ulatory proteins translates into an actual change in cellular 
iron content, such mechanistic studies will further under-
standing as to the downstream implications that follow a 
UPS impairment as a stimulus for iron overload as seen in 
PD-affected brains that may contribute to neuronal death. On 
the other hand, detailing the iron protein response network 
following exposure to a 1,2-HOPO iron chelator such as C6 
or C9, will further enlighten on the mechanistic basis for 
the protective response to lactacystin exposure that our data 
demonstrates.
The ligands C6, C9 and DFP differed in their respective 
metal coordination abilities and in their relative acidities, 
resulting in different metal-complex stability constants 
and hence this line of investigation was unable to afford a 
rationale for their pro-survival effects seen in this neurotoxin 
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cell model. We thus calculated the respective pM values 
to represent the amount of free metal in solution at physi-
ological pH, allowing us to compare the chelation power 
for various metals bound by the different ligands assessed 
in this study. The substituents present in C6 and C9 induced 
an increase of their affinity towards  Fe3+ by one order of 
magnitude compared to DFP. Both pFe values lay below 
those observed for transferrin (pFe = 23.62) so that, similar 
to DFP, C6 and C9 would therefore be expected to donate 
chelated iron to unsaturated transferrin, thus avoiding a loss 
of total iron and favoring its repositioning to other sites of 
use. This is similar to DFP, which was demonstrated as 
chelating excess intracellular labile iron and then redis-
tribute it to extracellular apotransferrin (Sohn et al. 2008, 
2011). This finding could suggest that, despite their rela-
tively low protonation constants, C6 and C9 exerted their 
neuroprotective and neurorescue effects in the lactacystin 
cellular model of PD by entering into SH-SY5Y cells, and 
then chelating intracellular labile  Fe3+, a suggestion that is in 
agreement with our previous study which showed that both 
C6 and C9 reduced intracellular  Fe3+ levels in similar cells 
in the 6-OHDA in vitro model of PD (Workman et al. 2015). 
However, it is also possible that C6 and C9 exerted their 
neuroprotective and neurorescue effects simply by chelating 
extracellular labile  Fe3+ instead. This depletion in extracel-
lular labile  Fe3+ would re-adjust the equilibrium between 
extracellular and intracellular labile  Fe3+ and would reduce 
apotransferrin-mediated influx of  Fe3+ into the cell, leading 
to a net reduction in the intracellular labile  Fe3+. In addition, 
whilst the low protonation constants of C6 and C9 suggest 
that neither compound is significantly capable of crossing 
into the SH-SY5Y cells through passive diffusion, we cannot 
rule out the possibility that these compounds could enter the 
cells as the neutral complex of other metals such as  Mg2+ 
or  Zn2+ or via an active transport mechanism (e.g., via a 
glucose transporter protein anchored in the cell membrane).
Distribution diagrams show that at physiological pH, 
C6 exist as neutral Fe(C6)3, in accordance with log  D7,4 
values of − 0.18(2), suggesting a less hydrophilic complex 
than DFP at a log D7,4 of − 2.60(5)) (Hayes et al. 2008). 
At similar conditions, ligand C9 existed as Fe(C9)33− and 
did not show significant migration to the n-octanol phase in 
our partition experiments, thus precluding the determina-
tion of its log D7,4 value. This finding indicates its highly 
hydrophilic nature and suggests that the neutral, relatively 
hydrophobic Fe(C6)3 complex would be able to leave the cell 
via passive diffusion and underscores that redistribution of 
 Fe3+ between cells is likely. On the other hand, the charged 
Fe(C9)33− complex would be highly unlikely to do so.
The DAergic cell death that characterizes PD pathol-
ogy is underpinned by oxidative stress, concomitant with 
cellular metabolic impairment (Halliwell and Gutteridge 
1984). Amongst other cell death mechanisms, lactacystin 
instigates a marked increase in oxidative stress and meta-
bolic failure, thereby modeling cellular effects seen in PD, 
with one study reporting that lactacystin treatment increased 
ROS production, which subsequently induced mitochondrial 
cytochrome c release indirectly, via translocation of the Bax 
protein, ultimately resulting in cell death (Perez-Alvarez 
et al. 2009). Iron is a potent generator of free-radicals via 
the Haber–Weiss reactions. In this regard, it is well docu-
mented that UPS impairment, as instigated by application of 
lactacystin, results in excessive iron, which in turn increases 
oxidative stress via overproduction of ROS (Halliwell and 
Gutteridge 1984; Dixon and Stockwell 2014). In turn, these 
events impair proteasomal function, thus promoting protein 
aggregates that result in eventual cell death (Rhodes and 
Ritz 2008).
Our data reveals that C6 treatment produced a greater 
reduction in iROS and eROS in lactacystin-treated cells than 
when cells were treated with C9. In addition, evaluation of 
the ability of C6 and C9 to act as radical traps using the 
DPPH assay revealed that C6 reached a much better effi-
ciency than C9, with C6 being nearly as efficient as DFP. 
It was found that 3-hydroxy-4(1H)-pyridinone derivatives, 
including DFP, are poor radical scavengers (Rhodes and 
Ritz 2008; Kayyali et al. 1998). Their ability to protect cells 
against oxidative damage is therefore not thought to be 
linked to the trapping of ROS. In fact, it was found that such 
metal chelators are effective at preventing  Fe3+ from taking 
part in Haber–Weiss reactions, but also that the inhibition 
is stoichiometry dependent, requiring an  FeL3 complex for 
inactivation (L = ligand) (El-Jammal and Templeton 1996; 
Merkofer et al. 2004, 2006; Devanur et al. 2008; Chaves 
et al. 2012). Their mode of action therefore appears to rather 
be linked to redox silencing of metals. It is also known that 
catechol groups (present in DA and l-DOPA) are pro-oxi-
dants in the presence of metals, with DFP that was found 
capable of preventing the pro-oxidant effect of this combina-
tion (Sun et al. 2018), thereby indicating multiple beneficial 
mechanisms of action.
Lactacystin’s neurotoxic mechanism of action relates to 
the covalent bond it forms with specific catalytic subunits of 
the 20S catalytic core of the proteasome, believed to regulate 
critical aspects for recognising and unfolding ubiquitinated 
proteins. This binding inhibits multiple peptidase activities 
of the enzyme complex, resulting in lack of proteasomal 
activity (Tomoda and Omura 2000). Based on this known 
mode of action of lactacystin, we postulated that besides 
iron chelation and an anti-ROS effect, C6 could potentially 
play an alternative role in protecting SH-SY5Y cells from 
lactacystin-induced neuronal damage, ultimately resulting in 
cell death, similar to what is seen in SNpc DAergic neurons 
in PD-affected human brains. In this regard we reasoned that 
the primary hydroxyl group of C6 could trap the reactive 
clasto-lactacystin β-lactone intermediate intracellularly, to 
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form the far less reactive lactacystin-C6 adduct, which is 
unable to acylate the N-terminal threonine residue in the 20S 
subunit of the proteasome. A similar nucleophilic attack by 
the N-hydroxyl group of C6 would only form an activated 
ester that would maintain the reactivity and therefore bio-
logical action of clasto-lactacystin β-lactone (Finkelstein 
et al. 2017). Thus, in addition to chelating and passivating 
intracellular iron, C6 could potentially act as a sacrificial 
compound that inactivates the reactive clasto-lactacystin 
β-lactone intermediate formed by lactacystin.
Accordingly, we assessed via 1H NMR whether the neu-
ronal protection and rescue effect we observed here in lacta-
cystin-treated cell cultures co-incubated with the novel iron 
chelators was due to the formation of an adduct between C6 
and lactacystin. In view of the novel compounds offering a 
potential treatment of PD, it was necessary to demonstrate 
that C6 is capable of preventing oxidative damage to neu-
rons regardless of which toxin in vitro model is used for 
generating excessive levels of ROS (e.g., 6-OHDA, MPTP or 
lactacystin). In due regard, the NMR and MS experimental 
data indicates that C6 is not capable of chemically degrading 
lactacystin in this manner. This suggests that in the presence 
of C6, lactacystin is not deactivated and remains capable of 
producing ROS and that C6 protects neurons against oxida-
tive stress-mediated neurodegeneration, regardless of the PD 
toxin used to generate excessive ROS for modeling PD-like 
cells. Since it appears that C6 does not degrade lactacystin, 
a similar NMR study on the interaction of lactacystin with 
C9 was not carried out in the present report.
Due to the interplay previously shown to exist between 
iron and α-SYN accumulation and aggregation (Golts et al. 
2002), iron chelators have been deemed a promising thera-
peutic strategy for reducing levels of α-SYN pathology seen 
in PD-affected brains. The current results showed that C6 
could normalise α-SYN levels that had been increased due 
to lactacystin treatment, while DFP and C9 were capable of 
reducing α-SYN levels substantially below the normal state, 
with C9 showing the most potent effect in this regard.
Our results show the therapeutic potential of the novel 
iron chelators, where it is well established that α-SYN aggre-
gation, as seen in PD brains, can be promoted by excess 
iron (Xiao et al. 2018). The central role that iron plays in 
LB promotion was further underlined by work reporting 
iron co-localization within LBs in the brains of PD patients 
(Castellani et al. 2000). The ability of metal-chelators such 
as PBT434, a novel quinazolinone compound bearing a 
metal-binding motif that holds moderate affinity, to prevent 
iron-mediated α-SYN toxicity, had previously been demon-
strated (Finkelstein et al. 2017). In this study, Finkelstein and 
others also revealed effective reduction of insoluble α-SYN 
levels in brain lysates taken from mice harboring the A53T 
α-SYN mutation that had been treated with the iron chela-
tor clioquinol, compared to placebo-treated control mice. 
In the current study we demonstrate the ability of DFP to 
reduce abnormally high levels of α-SYN in the SH-SY5Y 
lactacystin cell model of PD. This result adds to recent data 
showing that DFP is capable of reducing α-SYN aggregation 
in the hippocampi and cortices of transgenic mice bearing 
the A53T α-SYN mutation, with such mice that had been 
fed iron for exacerbating the motor phenotype (Carboni et al. 
2017). However, the protein reduction effect was weak, with 
significant variance detected between the mice.
Future investigations to identify the toxic nature of 
α-SYN induced by lactacystin, and to determine at what 
stage the test compounds, relative to DFP, may interfere 
in organized fibril assembly, sequencing as the formation 
of dimers, oligomers, protofibrillar structures and eventual 
mature linear fibers, may further enlighten on the therapeutic 
mechanism by which the presently tested novel iron chela-
tors showed ability to clear such protein abundance. Such 
additional characterisations, for example by utilizing immu-
noelectron microscopy, will strengthen the view proposed 
by the current data, that α-SYN accumulation is a target for 
C9 especially. In addition, studies to determine the capacity 
of C6 and C9, relative to DFP, to reduce other PD-relevant, 
aggregate-prone proteins such as ubiquitin, where lactacys-
tin had been shown to induce ubiquitinated protein aggrega-
tion in vitro (Yang et al. 2005), will give further insights as 
to how these novel iron chelators might act as agents induc-
ing deubiquitination or for degrading aggregated intracel-
lular proteins.
Work to determine the sequence of steps by which lac-
tacystin exposure produces toxic forms of intracellular 
protein also promises to enlighten on the mechanism of 
protein accumulation, where such insight will help develop 
this in vitro PD model for reflecting aspects of PD. In this 
regard, its currently unknown whether lactacystin induces 
a primary event that leads to aggregation of α-SYN due to 
its proteasome inhibitor effect, or whether this post-transla-
tional modification might rather occur firstly as a result of 
the reaction of lactacystin-induced excessive ROS produc-
tion with α-SYN.
Conclusions
For improving our understanding of the therapeutic mecha-
nisms of two novel 1,2-HOPO iron chelators (C6 and C9), 
we reveal, for the first time, their ability to both partially 
prevent and rescue against cell death due to lactacystin-
induced UPS inhibition, as was determined in an in vitro 
model of PD. We further revealed that such mitigating 
effects on the toxin-treated cells are likely due to the abil-
ity of the compounds to chelate and passivate intracellular 
labile iron, thereby reducing ROS production (accumulating 
both intracellularly and extracellularly) and prevent protein 
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aggregation, both of which are neuropathological hallmarks 
of the cellular dysfunction seen in PD. Direct trapping of 
the reactive clasto-lactacystin β-lactone intermediate by C6 
was not observed by NMR spectroscopy. Measurement of 
the stability constant values for  Fe3+ and  Cu2+ complexes 
confirmed that each of the compounds have a good affinity 
and selectivity for  Fe3+. Our results provide further evidence 
in support of labile iron as a viable therapeutic target and 
justifies further development of iron chelators as potential 
therapies for treating PD. Thus, our results suggest that 1,2-
HOPO chelators are a valuable class to explore further as 
potential disease-modifying agents against PD, in addition 
to 3-hydroxy-4(1H)-pyridinones.
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